<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00706511</url>
  </required_header>
  <id_info>
    <org_study_id>15870</org_study_id>
    <secondary_id>P50HD057796</secondary_id>
    <nct_id>NCT00706511</nct_id>
  </id_info>
  <brief_title>Metabolic Study of Sleep Apnea in Men and Women</brief_title>
  <official_title>Sleep and Metabolism in Obesity: Impact of Gender</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at the metabolic (use of energy) and hormonal features
      of sleep problems in men and women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity is a major risk factor for obstructive sleep apnea (OSA), a condition characterized
      by repetitive respiratory disturbances, intermittent hypoxia, sleep fragmentation by frequent
      microarousals and low amounts of deep slow wave sleep (SWS). Today, more than 10 million
      American women suffer from OSA. OSA has been identified as an independent risk factor for the
      metabolic syndrome. Because OSA is more prevalent in men than in women, a disproportionate
      number of studies of OSA and its consequences have been conducted in men. Thus, OSA has been
      characterized as a disorder associated with gender-based health care inequity. Recent
      evidence, including data from our group, suggests that reduced amounts and intensity of SWS
      (i.e. slow-wave activity [SWA]) may play a pivotal role in the development of metabolic and
      cardiovascular disturbances in obese men and women, particularly those with OSA. This project
      will focus on sex differences in SWA and their relationship with daytime sleepiness and
      metabolic vulnerability in obese men and women with and without OSA. We propose to
      simultaneously characterize: 1. sleep-wake regulation; 2. measures of diabetes risk; 3.
      measures of cardiovascular risk; and 4. profiles of sex steroids, cortisol and adipokines in
      a. obese men without OSA, b. obese men with OSA before and after treatment with continuous
      positive airway pressure (CPAP), c. obese pre-menopausal women without OSA, and d. obese
      pre-menopausal women with OSA before and after CPAP treatment. The completion of these
      interdisciplinary studies will provide a unique data set contrasting in obese women versus
      obese men the relationships between sleep and the metabolic syndrome, OSA and the metabolic
      syndrome and the impact of CPAP treatment on the metabolic syndrome. This work will provide
      important insights regarding the pathophysiology of OSA and its adverse consequences in obese
      men and women, and the basis for the development of effective sex-specific prevention and
      treatment strategies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2007</start_date>
  <completion_date type="Actual">August 22, 2012</completion_date>
  <primary_completion_date type="Actual">August 16, 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Polysomnography - Apnea-hypopnea Index (AHI)</measure>
    <time_frame>After 6 weeks of CPAP (Treatment)</time_frame>
    <description>apnea-hypopnea index: number of apneas and hypopneas per hour of recording; a measure of the severity of obstructive sleep apnea; varies from min=0 to max=120; AHI between 0 and &lt;5: no significant sleep apnea; AHI between 5 and &lt;15: mild sleep apnea; AHI between 15 and &lt;30: moderate sleep apnea; AHI of 30 and above: severe sleep apnea.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Polysomnography - Minutes of N3 Stage</measure>
    <time_frame>After 6 weeks of CPAP (Treatment)</time_frame>
    <description>Stage N3, sometimes referred to as &quot;delta sleep&quot; or &quot;slow wave sleep&quot;, is characterized by slow waves in the electro-encephalogram (EEG) that reflect synchronization of firing of cortical neurons. N3 sleep is considered the most restorative stage of sleep for both the brain and the rest of the body.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Polysomnography - Minutes of REM Stage</measure>
    <time_frame>After 6 weeks of CPAP (Treatment)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Polysomnography - Sleep Efficiency</measure>
    <time_frame>After 6 weeks of CPAP (Treatment)</time_frame>
    <description>Sleep efficiency: a measure of objective sleep quality; calculated from the polygraphic sleep recording as the ratio of time spent asleep during the scheduled sleep period to total scheduled sleep period. Expressed in %. Varies from 0% (the subject did not sleep at all) to 100% (the subject spent the entire scheduled sleep period asleep).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IVGTT (Intravenous Tolerance Test) - Sensitivity Index (SI)</measure>
    <time_frame>After treatment (6 weeks)</time_frame>
    <description>Sensitivity Index (SI): a measure of how much insulin the body needs to metabolize a given amount of glucose. SI is calculated using a mathematical model describing the profiles of blood glucose and serum insulin after intravenous glucose injection. SI varies from 0 to an undefined upper limit but generally under 20. Higher values of SI represent a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVGTT (Intravenous Tolerance Test) - Acute Insulin Response</measure>
    <time_frame>After treatment (6 weeks)</time_frame>
    <description>Acute Insulin Response is calculated as the area under the insulin curve for the first 19 minutes after intravenous glucose injection. &quot;Area under the insulin curve&quot; is expressed in pmol x min/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVGTT (Intravenous Tolerance Test) - Disposition Index (DI)</measure>
    <time_frame>After treatment (6 weeks)</time_frame>
    <description>Disposition Index (DI) is the product of sensitivity index (SI) by the amount of insulin secreted in response to blood glucose levels. It is a marker of the risk of type 2 diabetes. Low DI reflects a high risk of diabetes. DI can vary from 0 to an undefined upper limit. The physiological range for the Disposition Index is 500 to 5,000. Higher values represent a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Obstructive Sleep Apnea (OSA)</condition>
  <arm_group>
    <arm_group_label>Group with OSA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group without OSA</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CPAP</intervention_name>
    <description>CPAP (continuous positive airway pressure) treatment at home for 6 weeks</description>
    <arm_group_label>Group with OSA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obese (BMI of at least 30 kg/m2)

        Exclusion Criteria:

          -  Clinically significant depression

          -  Positive pregnancy test

          -  Diagnosis of diabetes mellitus

          -  Hypertension (systolic &gt; 140 mmHg and/or diastolic &gt; 90 mmHg) not well-controlled on
             stable medication with either ACE inhibitors or diuretics

          -  Habitual alcohol use

          -  Excessive caffeine intake of more than 300 mg/day

          -  Hemoglobin &lt; 11g/dL and/or hematocrit &lt; 33%

          -  Systemic illnesses, including heart, renal, liver, or malignant disease

          -  Taking steroid preparations (including oral contraceptives), medications known to
             alter insulin secretion and/or action, or medications known to influence sleep during
             the 2 months prior to starting the study

          -  Travel across time zones during the 4 weeks prior to starting the study

          -  Irregular sleeping habits (including shift work)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eve Van Cauter, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Department of Medicine, Section of Endocrinology, Diabetes &amp; Metabolism</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.uchospitals.edu/specialties/pulmonary/sleep-disorders/index.html</url>
    <description>University of Chicago Sleep Disorders Center</description>
  </link>
  <reference>
    <citation>Tasali E, Leproult R, Ehrmann DA, Van Cauter E. Slow-wave sleep and the risk of type 2 diabetes in humans. Proc Natl Acad Sci U S A. 2008 Jan 22;105(3):1044-9. doi: 10.1073/pnas.0706446105. Epub 2008 Jan 2.</citation>
    <PMID>18172212</PMID>
  </reference>
  <reference>
    <citation>Tasali E, Van Cauter E, Ehrmann DA. Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan;91(1):36-42. Epub 2005 Oct 11.</citation>
    <PMID>16219719</PMID>
  </reference>
  <reference>
    <citation>Tasali E, Mokhlesi B, Van Cauter E. Obstructive sleep apnea and type 2 diabetes: interacting epidemics. Chest. 2008 Feb;133(2):496-506. doi: 10.1378/chest.07-0828. Review.</citation>
    <PMID>18252916</PMID>
  </reference>
  <reference>
    <citation>Knutson KL, Spiegel K, Penev P, Van Cauter E. The metabolic consequences of sleep deprivation. Sleep Med Rev. 2007 Jun;11(3):163-78. Epub 2007 Apr 17. Review.</citation>
    <PMID>17442599</PMID>
  </reference>
  <reference>
    <citation>Van Cauter E, Holmback U, Knutson K, Leproult R, Miller A, Nedeltcheva A, Pannain S, Penev P, Tasali E, Spiegel K. Impact of sleep and sleep loss on neuroendocrine and metabolic function. Horm Res. 2007;67 Suppl 1:2-9. Epub 2007 Feb 15. Review.</citation>
    <PMID>17308390</PMID>
  </reference>
  <reference>
    <citation>Knutson KL, Ryden AM, Mander BA, Van Cauter E. Role of sleep duration and quality in the risk and severity of type 2 diabetes mellitus. Arch Intern Med. 2006 Sep 18;166(16):1768-74.</citation>
    <PMID>16983057</PMID>
  </reference>
  <reference>
    <citation>Latta F, Leproult R, Tasali E, Hofmann E, L'Hermite-Bal√©riaux M, Copinschi G, Van Cauter E. Sex differences in nocturnal growth hormone and prolactin secretion in healthy older adults: relationships with sleep EEG variables. Sleep. 2005 Dec;28(12):1519-24.</citation>
    <PMID>16408410</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>June 25, 2008</study_first_submitted>
  <study_first_submitted_qc>June 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2008</study_first_posted>
  <results_first_submitted>June 28, 2019</results_first_submitted>
  <results_first_submitted_qc>March 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 24, 2020</results_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OSA</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Gender</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Men With OSA</title>
          <description>Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
CPAP: CPAP (continuous positive airway pressure) treatment at home for 6 weeks</description>
        </group>
        <group group_id="P2">
          <title>Women With OSA</title>
          <description>Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
CPAP: CPAP (continuous positive airway pressure) treatment at home for 6 weeks</description>
        </group>
        <group group_id="P3">
          <title>Men Without OSA</title>
          <description>Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol</description>
        </group>
        <group group_id="P4">
          <title>Women Without OSA</title>
          <description>Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Men With OSA</title>
          <description>Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
CPAP: CPAP (continuous positive airway pressure) treatment at home for 6 weeks</description>
        </group>
        <group group_id="B2">
          <title>Women With OSA</title>
          <description>Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
CPAP: CPAP (continuous positive airway pressure) treatment at home for 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Men Without OSA</title>
          <description>Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol</description>
        </group>
        <group group_id="B4">
          <title>Women Without OSA</title>
          <description>Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.7" spread="6.5"/>
                    <measurement group_id="B2" value="35" spread="2.9"/>
                    <measurement group_id="B3" value="24.7" spread="1.5"/>
                    <measurement group_id="B4" value="31.9" spread="7.4"/>
                    <measurement group_id="B5" value="33.7" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Polysomnography - Apnea-hypopnea Index (AHI)</title>
        <description>apnea-hypopnea index: number of apneas and hypopneas per hour of recording; a measure of the severity of obstructive sleep apnea; varies from min=0 to max=120; AHI between 0 and &lt;5: no significant sleep apnea; AHI between 5 and &lt;15: mild sleep apnea; AHI between 15 and &lt;30: moderate sleep apnea; AHI of 30 and above: severe sleep apnea.</description>
        <time_frame>After 6 weeks of CPAP (Treatment)</time_frame>
        <population>One participant (a men with OSA) was excluded in the analysis because he did not complete the study. (See the participant flow chart)</population>
        <group_list>
          <group group_id="O1">
            <title>Men With OSA</title>
            <description>Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
CPAP: CPAP (continuous positive airway pressure) treatment at home for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Women With OSA</title>
            <description>Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
CPAP: CPAP (continuous positive airway pressure) treatment at home for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Men Without OSA</title>
            <description>Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol</description>
          </group>
          <group group_id="O4">
            <title>Women Without OSA</title>
            <description>Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Polysomnography - Apnea-hypopnea Index (AHI)</title>
          <description>apnea-hypopnea index: number of apneas and hypopneas per hour of recording; a measure of the severity of obstructive sleep apnea; varies from min=0 to max=120; AHI between 0 and &lt;5: no significant sleep apnea; AHI between 5 and &lt;15: mild sleep apnea; AHI between 15 and &lt;30: moderate sleep apnea; AHI of 30 and above: severe sleep apnea.</description>
          <population>One participant (a men with OSA) was excluded in the analysis because he did not complete the study. (See the participant flow chart)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="13.7"/>
                    <measurement group_id="O2" value="0.7" spread="0.8"/>
                    <measurement group_id="O3" value="6" spread="5.2"/>
                    <measurement group_id="O4" value="1.1" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Polysomnography - Minutes of N3 Stage</title>
        <description>Stage N3, sometimes referred to as &quot;delta sleep&quot; or &quot;slow wave sleep&quot;, is characterized by slow waves in the electro-encephalogram (EEG) that reflect synchronization of firing of cortical neurons. N3 sleep is considered the most restorative stage of sleep for both the brain and the rest of the body.</description>
        <time_frame>After 6 weeks of CPAP (Treatment)</time_frame>
        <population>One participant (a men with OSA) was excluded in the analysis because he did not complete the study. (See the participant flow chart)</population>
        <group_list>
          <group group_id="O1">
            <title>Men With OSA</title>
            <description>Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
CPAP: CPAP (continuous positive airway pressure) treatment at home for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Women With OSA</title>
            <description>Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
CPAP: CPAP (continuous positive airway pressure) treatment at home for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Men Without OSA</title>
            <description>Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol</description>
          </group>
          <group group_id="O4">
            <title>Women Without OSA</title>
            <description>Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Polysomnography - Minutes of N3 Stage</title>
          <description>Stage N3, sometimes referred to as &quot;delta sleep&quot; or &quot;slow wave sleep&quot;, is characterized by slow waves in the electro-encephalogram (EEG) that reflect synchronization of firing of cortical neurons. N3 sleep is considered the most restorative stage of sleep for both the brain and the rest of the body.</description>
          <population>One participant (a men with OSA) was excluded in the analysis because he did not complete the study. (See the participant flow chart)</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.1" spread="42.6"/>
                    <measurement group_id="O2" value="53.7" spread="28.7"/>
                    <measurement group_id="O3" value="75.7" spread="22.4"/>
                    <measurement group_id="O4" value="66.6" spread="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Polysomnography - Minutes of REM Stage</title>
        <time_frame>After 6 weeks of CPAP (Treatment)</time_frame>
        <population>One participant (a men with OSA) was excluded in the analysis because he did not complete the study. (See the participant flow chart)</population>
        <group_list>
          <group group_id="O1">
            <title>Men With OSA</title>
            <description>Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
CPAP: CPAP (continuous positive airway pressure) treatment at home for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Women With OSA</title>
            <description>Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
CPAP: CPAP (continuous positive airway pressure) treatment at home for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Men Without OSA</title>
            <description>Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol</description>
          </group>
          <group group_id="O4">
            <title>Women Without OSA</title>
            <description>Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Polysomnography - Minutes of REM Stage</title>
          <population>One participant (a men with OSA) was excluded in the analysis because he did not complete the study. (See the participant flow chart)</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" spread="24.1"/>
                    <measurement group_id="O2" value="101.5" spread="10.9"/>
                    <measurement group_id="O3" value="107.8" spread="28.2"/>
                    <measurement group_id="O4" value="111.1" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Polysomnography - Sleep Efficiency</title>
        <description>Sleep efficiency: a measure of objective sleep quality; calculated from the polygraphic sleep recording as the ratio of time spent asleep during the scheduled sleep period to total scheduled sleep period. Expressed in %. Varies from 0% (the subject did not sleep at all) to 100% (the subject spent the entire scheduled sleep period asleep).</description>
        <time_frame>After 6 weeks of CPAP (Treatment)</time_frame>
        <population>One participant (a men with OSA) was excluded in the analysis because he did not complete the study. (See the participant flow chart)</population>
        <group_list>
          <group group_id="O1">
            <title>Men With OSA</title>
            <description>Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
CPAP: CPAP (continuous positive airway pressure) treatment at home for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Women With OSA</title>
            <description>Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
CPAP: CPAP (continuous positive airway pressure) treatment at home for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Men Without OSA</title>
            <description>Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol</description>
          </group>
          <group group_id="O4">
            <title>Women Without OSA</title>
            <description>Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol</description>
          </group>
        </group_list>
        <measure>
          <title>Polysomnography - Sleep Efficiency</title>
          <description>Sleep efficiency: a measure of objective sleep quality; calculated from the polygraphic sleep recording as the ratio of time spent asleep during the scheduled sleep period to total scheduled sleep period. Expressed in %. Varies from 0% (the subject did not sleep at all) to 100% (the subject spent the entire scheduled sleep period asleep).</description>
          <population>One participant (a men with OSA) was excluded in the analysis because he did not complete the study. (See the participant flow chart)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" spread="6.2"/>
                    <measurement group_id="O2" value="89.9" spread="6.5"/>
                    <measurement group_id="O3" value="86.5" spread="6.3"/>
                    <measurement group_id="O4" value="89.7" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IVGTT (Intravenous Tolerance Test) - Sensitivity Index (SI)</title>
        <description>Sensitivity Index (SI): a measure of how much insulin the body needs to metabolize a given amount of glucose. SI is calculated using a mathematical model describing the profiles of blood glucose and serum insulin after intravenous glucose injection. SI varies from 0 to an undefined upper limit but generally under 20. Higher values of SI represent a better outcome.</description>
        <time_frame>After treatment (6 weeks)</time_frame>
        <population>One participant (a men with OSA) was excluded in the analysis because he did not complete the study. (See the participant flow chart)</population>
        <group_list>
          <group group_id="O1">
            <title>Men With OSA</title>
            <description>Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
CPAP: CPAP (continuous positive airway pressure) treatment at home for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Women With OSA</title>
            <description>Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
CPAP: CPAP (continuous positive airway pressure) treatment at home for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Men Without OSA</title>
            <description>Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol</description>
          </group>
          <group group_id="O4">
            <title>Women Without OSA</title>
            <description>Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol</description>
          </group>
        </group_list>
        <measure>
          <title>IVGTT (Intravenous Tolerance Test) - Sensitivity Index (SI)</title>
          <description>Sensitivity Index (SI): a measure of how much insulin the body needs to metabolize a given amount of glucose. SI is calculated using a mathematical model describing the profiles of blood glucose and serum insulin after intravenous glucose injection. SI varies from 0 to an undefined upper limit but generally under 20. Higher values of SI represent a better outcome.</description>
          <population>One participant (a men with OSA) was excluded in the analysis because he did not complete the study. (See the participant flow chart)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.226" spread="0.642"/>
                    <measurement group_id="O2" value="1.106" spread="0.44"/>
                    <measurement group_id="O3" value="2.32" spread="1.15"/>
                    <measurement group_id="O4" value="4.195" spread="3.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IVGTT (Intravenous Tolerance Test) - Acute Insulin Response</title>
        <description>Acute Insulin Response is calculated as the area under the insulin curve for the first 19 minutes after intravenous glucose injection. &quot;Area under the insulin curve&quot; is expressed in pmol x min/L.</description>
        <time_frame>After treatment (6 weeks)</time_frame>
        <population>One participant (a men with OSA) was excluded in the analysis because he did not complete the study. (See the participant flow chart)</population>
        <group_list>
          <group group_id="O1">
            <title>Men With OSA</title>
            <description>Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
CPAP: CPAP (continuous positive airway pressure) treatment at home for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Women With OSA</title>
            <description>Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
CPAP: CPAP (continuous positive airway pressure) treatment at home for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Men Without OSA</title>
            <description>Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol</description>
          </group>
          <group group_id="O4">
            <title>Women Without OSA</title>
            <description>Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol</description>
          </group>
        </group_list>
        <measure>
          <title>IVGTT (Intravenous Tolerance Test) - Acute Insulin Response</title>
          <description>Acute Insulin Response is calculated as the area under the insulin curve for the first 19 minutes after intravenous glucose injection. &quot;Area under the insulin curve&quot; is expressed in pmol x min/L.</description>
          <population>One participant (a men with OSA) was excluded in the analysis because he did not complete the study. (See the participant flow chart)</population>
          <units>pmol x min/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1061" spread="736"/>
                    <measurement group_id="O2" value="623" spread="338"/>
                    <measurement group_id="O3" value="734" spread="784"/>
                    <measurement group_id="O4" value="1020" spread="564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IVGTT (Intravenous Tolerance Test) - Disposition Index (DI)</title>
        <description>Disposition Index (DI) is the product of sensitivity index (SI) by the amount of insulin secreted in response to blood glucose levels. It is a marker of the risk of type 2 diabetes. Low DI reflects a high risk of diabetes. DI can vary from 0 to an undefined upper limit. The physiological range for the Disposition Index is 500 to 5,000. Higher values represent a better outcome.</description>
        <time_frame>After treatment (6 weeks)</time_frame>
        <population>One participant (a men with OSA) was excluded in the analysis because he did not complete the study. (See the participant flow chart)</population>
        <group_list>
          <group group_id="O1">
            <title>Men With OSA</title>
            <description>Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
CPAP: CPAP (continuous positive airway pressure) treatment at home for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Women With OSA</title>
            <description>Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
CPAP: CPAP (continuous positive airway pressure) treatment at home for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Men Without OSA</title>
            <description>Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol</description>
          </group>
          <group group_id="O4">
            <title>Women Without OSA</title>
            <description>Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol</description>
          </group>
        </group_list>
        <measure>
          <title>IVGTT (Intravenous Tolerance Test) - Disposition Index (DI)</title>
          <description>Disposition Index (DI) is the product of sensitivity index (SI) by the amount of insulin secreted in response to blood glucose levels. It is a marker of the risk of type 2 diabetes. Low DI reflects a high risk of diabetes. DI can vary from 0 to an undefined upper limit. The physiological range for the Disposition Index is 500 to 5,000. Higher values represent a better outcome.</description>
          <population>One participant (a men with OSA) was excluded in the analysis because he did not complete the study. (See the participant flow chart)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1159" spread="789"/>
                    <measurement group_id="O2" value="683" spread="531"/>
                    <measurement group_id="O3" value="1257" spread="849"/>
                    <measurement group_id="O4" value="3718" spread="3270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group With OSA</title>
          <description>Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
CPAP: CPAP (continuous positive airway pressure) treatment at home for 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>Group Without OSA</title>
          <description>Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eve Van Cauter, PhD</name_or_title>
      <organization>University of Chicago</organization>
      <phone>773-702-0169</phone>
      <email>evcauter@bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

